Orniona 0.1% (estriol) vaginal cream 15g

Orniona® is indicated for use in women:
- as menopausal hormone therapy (MHT): treatment of atrophy of the mucous membrane of the lower urinary and genital tracts associated with estrogen deficiency in postmenopausal women;
- pre- and postoperative therapy in postmenopausal women undergoing surgery through the vaginal approach;
- as an adjunctive diagnostic tool in case of a suspicious result of a cervical smear for oncocytology (PAP test, class III) in menopausal women when abnormal cells are detected against the background of atrophic changes.

Do not use Orniona®:
- if you are allergic to estriol or any other components of the drug (listed in section 6 of the package leaflet);
- if you have been diagnosed with, have had in the past, or are suspected of having breast cancer (BC);
- if you have been diagnosed with or are suspected of having estrogen-dependent tumors (e.g. endometrial cancer);
- if you have vaginal bleeding of unclear etiology (cause);
- if you have untreated endometrial hyperplasia (excessive growth of the inner lining of the uterine cavity);
- if you have venous thromboembolism (VTE) currently or in the past (diagnoses such as deep vein thrombosis, pulmonary embolism);
- if you have confirmed thrombophilic disorders (e.g. protein C, protein S or antithrombin III deficiency, etc.);
- if you have arterial thrombosis or thromboembolism, including myocardial infarction, stroke, cerebrovascular accident (cerebral circulatory insufficiency); or prodromal (intermediate) conditions (including transient ischemic attack, angina) are currently or have been observed previously;
- if you have a liver disease in the acute stage or have had a liver disease in the past, after which liver function indicators in the blood test did not return to normal;
- if you have porphyria (a rare genetic disease characterized by abdominal pain and skin ulcers);
- if you are pregnant;
- if you are breastfeeding.